Evidence map›Paper›PMID 34975832›Full record

ArticleFrontiers in immunology2021

CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study.

Mette Scheller Nissen, Matias Ryding, Anna Christine Nilsson, Jonna Skov Madsen, Dorte Aalund Olsen, Ulrich Halekoh, Magnus Lydolph, Zsolt Illes, Morten Blaabjerg

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Neuroglial biomarkers in autoimmune encephalitis: advances in diagnosis, prognosis, and pathophysiological insights.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Article
  6. Review
  7. Review
  8. Neuroglial markers of damage in autoimmune neurology.Therapeutic advances in neurological disorders · 2026
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mette Scheller NissenDepartment of Neurology, Odense University Hospital, Odense, Denmark.
Matias RydingDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.
Anna Christine NilssonDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.
Jonna Skov MadsenDepartment of Biochemistry and Immunology, Lillebælt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Dorte Aalund OlsenDepartment of Biochemistry and Immunology, Lillebælt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
Ulrich HalekohDepartment of Epidemiology, Biostatistics and Biodemography, Institute of Public Health, University of Southern Denmark, Odense, Denmark.
Magnus LydolphDanish National Biobank, Statens Serum Institut, Copenhagen, Denmark.
Zsolt IllesDepartment of Neurology, Odense University Hospital, Odense, Denmark.
Morten BlaabjergDepartment of Neurology, Odense University Hospital, Odense, Denmark.
University of Southern Denmark · DKLillebaelt Hospital · DKDanmarks Nationalbank · DKOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: The two most common autoimmune encephalitides (AE), Methods: Patients were included from the National Danish AE cohort (2009-present) and diagnosed based upon autoantibody positivity and diagnostic consensus criteria. CSF-NfL was analyzed by single molecule array technology. Clinical and diagnostic information was retrospectively evaluated and related to NfL levels at baseline and follow-up. NMDAR-AE patients were subdivided into: idiopathic/teratoma associated or secondary NMDAR-AE (post-viral or concomitant with malignancies/demyelinating disease). Results: A total of 74 CSF samples from 53 AE patients (37 NMDAR and 16 LGI1 positive) were included in the study. Longitudinal CSF-NfL levels was measured in 21 patients. Median follow-up time was 23.8 and 43.9 months for NMDAR and LGI1-AE respectively. Major findings of this study are: i) CSF-NfL levels were higher in LGI1-AE than in idiopathic/teratoma associated NMDAR-AE at diagnosis; ii) CSF-NfL levels in NMDAR-AE patients distinguished idiopathic/teratoma cases from cases with other underlying etiologies (post-viral or malignancies/demyelinating diseases) and iii) Elevated CSF-NfL at diagnosis seems to be associated with worse long-term disease outcomes in both NMDAR and LGI1-AE. Discussion: CSF-NfL measurement may be beneficial as a prognostic biomarker in NMDAR and LGI1-AE, and high CSF-NfL could foster search for underlying etiologies in NMDAR-AE. Further studies on larger cohorts, using standardized methods, are warranted.

Indexed as

AdolescentAdultAgedAged, 80 and overAnti-N-Methyl-D-Aspartate Receptor EncephalitisBiomarkersChildDemyelinating DiseasesDenmarkEncephalitis, Herpes SimplexFemaleFollow-Up StudiesHumansIntracellular Signaling Peptides and ProteinsLeukocytosisLimbic EncephalitisBiomarkersIntracellular Signaling Peptides and ProteinsLGI1 protein, humanneurofilament protein LNeurofilament Proteinsautoimmune encephalitis (AE)biomarkerLGI1 encephalitisneurofilament light (NfL) chainNMDAR encephalitis (NMDARE)outcome

Identifiers

PMID34975832
PMCPMC8716734
OpenAlexW4200492122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.